Category 'CLAIMS'

Wednesday, February 14, 2018
Category : NEWS, CLAIMS, INGREDIENTS, CLINICAL EVIDENCE | Author : experts | Comment : No Comments

 NOL, Nutraveris Online, the most efficient data solution to create, keep up-to-date and launch your products in the 28 EU member states, used for 10years by more than 500 industry leaders informs you:


The effects of resveratrol on blood pressure are controversial. Consequently, the authors of this systematic review and meta-analysis was to analyze randomized and controlled trials to clarify the effects of resveratrol on blood pressure. 17 clinical trials have been identified.




Overall, resveratrol had no significant effect on systolic blood pressure (WMD= -2.5 mHg, 95% CI: -5.5, 0.6 mmHg, p = 0.116), diastolic blood pressure (WMD= -0.5 mmHg, 95% CI: -2.2, 1.3 mmHg, p = 0.613) and mean arterial blood pressure (WMD= -1.3 mmHg,95% CI: -2.8, 0.1 mmHg, p = 0.070).

However, sub-group analysis showed that resveratrol may affect blood pressure for high daily intakes (> 300 mg/day) or in diabetic patients. There was a positive association between the resveratrol lowering effect on systolic blood pressure and BMI at baseline (p = 0.04).


In conclusion, resveratrol has no clear effects on blood pressure in the general population, but may have significant hypertensive effects at high dosage (> 300 mg/day) and in diabetic subjects.


Fogacci F, Tocci G, Presta V, Fratter A, Borghi C, Cicero AFG. Effect of resveratrol on blood pressure: A systematic review and meta-analysis of randomized, controlled, clinical trials. Crit Rev Food Sci Nutr. 2018 Jan 23:1-14.


This information has been sourced by NOL, a collaborative and complete tool which contains all Regulatory, Scientific and Marketing data

  • It solves all regulatory issues since it contains the required information on all ingredients authorized in the 28 European member states…on regulatory status, health claims, authority opinions
  • It protects your investments since it is updated in real time with reliable quality information analyzed and reviewed by our experts, available hotline.
  • It enables you to be the most responsive with monthly reports and live alerts and a personal use of the information with a report editing tool and customizable bookmarks.

With NOL let’s : 

  • Formulate new innovative products
  • Check if your already existing formulas are still compliant with the in force regulations
  • Adapt your existing formulas to the requirements of other European countries where you are willing to export them
  • Do scientific & regulatory & marketing monitoring which enable to anticipate the withdrawal of products, the safety issues, new interesting scientific studies, the arrival of new players on the market…


More information on

Contact our Scientific & Regulatory experts at NUTRAVERIS, +33 2 96 76 54 87

Monday, January 8, 2018
Category : NEWS, CLAIMS, INGREDIENTS | Author : experts | Comment : No Comments

Thanks to its substantial experience in the novel food process and management in Europe, Nutraveris has just obtained a new success further to the recognition by the European Food Safety Authority (EFSA) that the orthosilicic acid-vanillin complex (OSA-VC) is safe for human consumption.

EFSA’s opinion comes after a complete evaluation of the application in accordance with the previous novel food regulation (regulation (EC) No 258/97). The ingredient, a dietary source of silicon, has been evaluated by Member States and by EFSA, with deep and important discussions on all the aspects of a novel food application (i.e. characterization of the ingredient, bioavailability and safety).



This new success for Nutraveris confirms its position as a leading consultancy in the European novel food approval.

Nutraveris has indeed all the skills and experience to obtain EU authorizations.


Do not hesitate to contact our Scientific & Regulatory experts for further information at NUTRAVERIS

Hotline Nutraveris: +33 2 96 76 54 87 ,


Monday, February 13, 2017
Category : NEWS, CLAIMS | Author : experts | Comment : No Comments

EU health claim specialists say EFSA guidance issued last week clarifies application procedures but changes nothing of the infamous pharma-style scientific requirements that have denied 1000s of claims across the EU bloc of 28 nations…


Find below the publication of NUTRAINGREDIENT:

Monday, September 30, 2013
Category : CLAIMS, NUTRILEGAL | Author : experts | Comment : No Comments

Three Article 13.5 health claims which had received positive opinions from EFSA in 2010, 2011 and 2012 are now authorized according to Regulation (EU) N° 851/2013 of 3 September 2013:

–       “Replacing sugar-containing, acidic drinks, such as soft drinks (typically 8-12 g sugars/100 ml), with reformulated drinks contributes to the maintenance of tooth mineralization” (Petitioner: GlaxoSmithKline Services Unlimited)

–      “Consumption of products high in slowly digestible starch (SDS) raises blood glucose concentration less after a meal compared to products low in SDS” (Petitioner: Mondelēz International group)

–      “Cocoa flavanols help maintain the elasticity of blood vessels, which contributes to normal blood flow” (Petitioner: Barry Callebaut Belgium nv.)

These 3 health claims are restricted to the use of their petitioner for a period of five years.

Moreover EFSA published in July 6 positive opinions on:

2 Article 14 health claims – Disease risk reduction:

–      Limicol® (combination of numerous ingredients) and reduction of blood LDL-cholesterol concentrations

–      Increasing maternal folate status by supplemental folate intake and reduced risk of neural tube defects

3 Article 14 health claims – Children’s development & health, for infants and children up to three years:

–      Magnesium and contribution to normal development of bone

–      Iron and contribution to normal cognitive development

–      Vitamin A and contribution to normal development and function of the immune system

1 positive opinion on an Article 13.5 health claim:

–      “Non-fermentable” carbohydrates (of which Nutriose®) and maintenance of tooth mineralisation by decreasing tooth demineralization.

Experts from Nutraveris consultancy are at your disposal for bringing their know-how concerning your projects of new specific health claims.

Friday, November 30, 2012
Category : CLAIMS, INGREDIENTS, INNOVATION | Author : experts | Comment : No Comments
Tags: , , , , , , ,

Regulation (EC) n°1924/2006 has introduced the definition of a Health Claim. In practical terms, all common ways to promote a supplement or health product, even a brand name or pictures, is now considered as a health claim. It took 5 years for EFSA to review all the claims on the market (for 44,000 dossiers submitted) and build the positive list with authorized claims which were validated by the European Commission. They published in May 2012, and it became law on June 14th; a 6 months transition period was granted to be compliant, and so after December 14th, authorities of EU member states will be able to declare all non-compliant products as illegal.

The next steps are easy to guess: there are 2 options.

Option 1: if you want to use claims, make sure that the ingredients in your formula are on the regulation 432/2012 (positive list) to provide the health benefits you want to promote.

Option 2: just take Health Claim out of your labels and communication tools (website included), and rely on consumers’ knowledge about ingredient functionality.

Indeed, strong criteria were applied to evaluate the science behind messages, except on very basic substances (vitamins & minerals). As a result, only 222 claims have been approved & included into the positive list. And most of them are trivial wordings. The immediate impact on store shelves: all products will be promoted with the same claims, based on the same ingredients.

Standing out of the competition is going to take a lot more creativity. Of course, you may still work on the brand, the product, or on the distribution strategy. But to get real consumer loyalty, you have to bring them innovation, with truly perceptible health improvement.

That’s the direction the market seems to take, after a few months of “wait and see”. The best way to get ahead of the competition is obviously to move first. Companies should push this development toward getting EFSA approvals, fulfilling criteria of the scientific panel, to continue bringing innovative healthy products to Europe’s 500 million potential consumers.